Kevin Kabler focuses his practice on building and managing patent portfolios for companies and institutions in the life sciences industry in the fields of immuno-oncology, antibodies, personalized medicine, vaccines, genetics, biologics, RNAi, stem cells and immunotherapy. He provides strategic patent counseling and due diligence to clients at all stages of the business cycle in the life sciences industry. He analyzes and evaluates third-party patents for risk reduction from assertions as well as investment purposes. He also analyzes patent portfolios for assertion and enforcement purposes against third parties. Kevin has extensive experience in developing and managing patent portfolios for companies and institutions in the life sciences industry, including preparation and prosecution of domestic and international patent applications. Kevin also advises investors in assessing the competitive landscape, technology and intellectual property assets and risks associated with target investments.
Kevin has particularly deep technical and legal experience in the fields of immuno-oncology and immunotherapy, including checkpoint inhibitors, CAR-T cells and cancer vaccines. Kevin began his hands-on laboratory work in 2002 studying methods of using checkpoint inhibitors within professional antigen presenting cells for use in cancer vaccines. This work resulted in Kevin being a named inventor on multiple patents and a lead author on numerous scientific papers in leading peer-reviewed journals including Nature Medicine and Nature Biotechnology. In his legal career, Kevin has deepened his expertise in immuno-oncology and immunotherapy by counseling leading companies whose technologies range from antibodies to personalized cancer vaccines on the protection and exploitation of their IP and business in the market.
Kevin is also focused on technology that sits at the nexus between traditional biological and medical research and data science. He is a co-founder of a Fenwick working group with Andrew Whitehead that is rapidly iterating on how to improve patents written in this space to successfully navigate the shifting, modern legal landscape that has significantly impacted what subject matter is deemed eligible for patenting.
Kevin began his career at Fenwick & West as a patent agent in 2007. Prior to joining Fenwick & West, Kevin was a postdoctoral fellow in the laboratory of Nobel Laureate J. Michael Bishop at the University of California, San Francisco.